SPY319.40+8.04 2.58%
DIA271.51+8.18 3.11%
IXIC9,814.08+198.27 2.06%

Vaccinex Will Present Updated Results From CLASSICAL-Lung, Phase 1b/2 Study Of Pepinemab In Combo With Avelumab In Non-Small Cell Lung Cancer At ASCO On May 29

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced a poster

Benzinga · 05/13/2020 21:32

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced a poster presentation highlighting interim results from CLASSICAL-Lung, the Company’s Phase 1b/2 study of pepinemab in combination with the anti-PD-L1 checkpoint inhibitor BAVENCIO® (avelumab) in non-small cell lung cancer (NSCLC), at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, being held virtually May 29-31, 2020.

“We are pleased to announce that updated data from the CLASSICAL-Lung trial of combination treatment with pepinemab and avelumab confirms earlier signs of anti-tumor activity, most notably in patients for whom  previous treatment with anti–PD-1/PD-L1 therapies failed and those who have PD-L1–negative or –low tumors,” said Dr. Maurice Zauderer, President and CEO of Vaccinex. “We believe this uniquely positions pepinemab to help the many patients with NSCLC who do not respond to PDx therapies, and we are looking forward to continuing to advance pepinemab through development.” 

Details on Vaccinex’s poster discussion presentation at ASCO:

Abstract Number: 3011
Title: Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC
Session: Developmental Therapeutics – Immunotherapy
Presenter: Michael Rahman Shafique, M.D., Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute
Date: Available on demand beginning May 29 at 8:00 a.m. EDT.